Please ensure Javascript is enabled for purposes of website accessibility

Why Flexion Therapeutics Lost A Quarter Of Its Value Today

By Todd Campbell - Sep 9, 2015 at 2:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A disappointing trial outcome for Flexion Therapeutics may not tell the whole story.

What: After announcing yesterday afternoon a key mid stage clinical trial failure, shares in Flexion Therapeutics, (FLXN) tumbled by 28% earlier today.

So what: Flexion Therapeutics' lead product candidate, FX006, was being studied to reduce pain in patients with moderate-to-severe osteoarthritis of the knee.

Unfortunately, results from a phase 2b study evaluating FX006 in 310 of these patients failed to show that it provides better pain relief than a placebo at 12 weeks of treatment.

Now what: Flexion Therapeutics may be able to salvage FX006, however, because a sensitivity analysis taking into consideration people who dropped out of the trial resulted in a positive finding.

Additionally, positive efficacy was noted at several other time periods throughout the trial, including for average pain relief over weeks one through 12. Also, Flexion Therapeutics analysis shows that a higher 40 mg dose of FX006 works better than a lower 20 mg dose, which leaves the door open for developing the higher dose and abandoning the lower dose in the future.

Because Flexion Therapeutics' additional analysis suggests that FX006 works in some patients, investors might want to wait for results from an ongoing phase 3 trial of the drug before buying or selling Flexion Therapeutics shares. Results from that trial are expected early next year, so stay tuned.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Flexion Therapeutics, Inc. Stock Quote
Flexion Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.